GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Purchase Of Business

Shield Therapeutics (LSE:STX) Purchase Of Business : £0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Purchase Of Business?

Shield Therapeutics's purchase of business for the six months ended in Dec. 2024 was £0.00 Mil. It means Shield Therapeutics spent £0.00 Mil on purchasing business. Shield Therapeutics's purchase of business for the trailing twelve months (TTM) ended in Dec. 2024 was £0.00 Mil.

Compared with last quarter (£0.00 Mil in Jun. 2024 ), Shield Therapeutics spent the same money on purchasing business in Dec. 2024 (£0.00 Mil).

Shield Therapeutics Purchase Of Business Historical Data

The historical data trend for Shield Therapeutics's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Purchase Of Business Chart

Shield Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Purchase Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Shield Therapeutics Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Purchase Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Shield Therapeutics Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Purchase Of Business
Comparable Companies
AQSE:ANA LSE:PXS LSE:EAH LSE:CEL LSE:N4P ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR
Traded in Other Exchanges
1JS:Germany
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Website
https://www.shieldtherapeutics.com
Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.